Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide YY and appetite control.

B M C McGowan1, S R Bloom

  • 1Department of Metabolic Medicine, Imperial College Faculty of Medicine, 6th Floor Commonwealth Building, Hammersmith Campus, DuCane Road, London W12 0NN, UK.

Current Opinion in Pharmacology
|November 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Central and peripheral administration of human relaxin-2 to adult male rats inhibits food intake.

Diabetes, obesity & metabolism·2010
Same author

The effect of a 12-week low glycaemic index diet on heart disease risk factors and 24 h glycaemic response in healthy middle-aged volunteers at risk of heart disease: a pilot study.

European journal of clinical nutrition·2007
Same author

Central relaxin-3 administration causes hyperphagia in male Wistar rats.

Endocrinology·2005
Same author

Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3' UTR and factor V Leiden mutations.

American journal of hematology·2003
Same author

The effects of various peptides on human isolated gut muscle.

The Journal of pharmacy and pharmacology·1992
Same author

The presence, characterisation and synthesis of neuromedin B in the human pituitary gland.

Neuroendocrinology·1992
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Peptide YY (PYY) is a gut hormone that can suppress appetite. Stress can block its effects, but acclimatization allows PYY(3-36) to effectively reduce food intake, offering potential obesity treatments.

Area of Science:

  • Neuroendocrinology
  • Gastrointestinal hormones

Background:

  • Peptide YY (PYY) is a key gastrointestinal hormone.
  • PYY(3-36), a circulating form, inhibits food intake.
  • Stress can interfere with PYY's anorexigenic effects.

Purpose of the Study:

  • To investigate the role of PYY(3-36) in appetite regulation.
  • To understand the conditions under which PYY(3-36) is effective.
  • To explore PYY(3-36) as a potential obesity therapeutic.

Main Methods:

  • Peripheral administration of PYY(3-36).
  • Assessment of food intake inhibition.
  • Consideration of animal acclimatization to stress.

Main Results:

Related Experiment Videos

  • PYY(3-36) administration inhibits food intake when stress is controlled.
  • Acclimatization is crucial for PYY(3-36) efficacy.
  • Evidence points to the hypothalamic Y(2) receptor as the target.

    • Conclusions:

    • PYY(3-36) is a potent anorexigenic hormone.
    • Therapeutic strategies targeting PYY may help combat obesity.
    • Low PYY(3-36) levels in overweight individuals suggest its therapeutic potential.